{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T05:29:58Z","timestamp":1768714198575,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004704","name":"National Research Council of Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010724","name":"Health Systems Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010724","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007693","name":"King Chulalongkorn Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002873","name":"Chulalongkorn University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002873","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.vaccine.2022.04.043","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T00:40:44Z","timestamp":1650242444000},"page":"3203-3209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data"],"prefix":"10.1016","volume":"40","author":[{"given":"Nasamon","family":"Wanlapakorn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nungruthai","family":"Suntronwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harit","family":"Phowatthanasathian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritthideach","family":"Yorsaeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thanunrat","family":"Thongmee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Preeyaporn","family":"Vichaiwattana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chompoonut","family":"Auphimai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lakkhana","family":"Wongsrisang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirapa","family":"Klinfueng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natthinee","family":"Sudhinaraset","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Poovorawan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10303","key":"10.1016\/j.vaccine.2022.04.043_b0005","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(21)01694-9","article-title":"Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial","volume":"398","author":"Liu","year":"2021","journal-title":"Lancet"},{"issue":"10295","key":"10.1016\/j.vaccine.2022.04.043_b0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(21)01420-3","article-title":"CombiVacS Study Group. Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"398","author":"Borobia","year":"2021","journal-title":"Lancet"},{"issue":"10289","key":"10.1016\/j.vaccine.2022.04.043_b0015","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1016\/S0140-6736(21)01115-6","article-title":"Com-COV Study Group. Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data","volume":"397","author":"Shaw","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.043_b0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"Barros-Martins","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.043_b0025","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S2213-2600(21)00357-X","article-title":"Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study","volume":"9","author":"Hillus","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2022.04.043_b0030","doi-asserted-by":"crossref","first-page":"6520","DOI":"10.1016\/j.vaccine.2021.09.052","article-title":"A phase III, observer-blind, randomized, placebo-controlled study of the efficacy, safety, and immunogenicity of SARS-CoV-2 inactivated vaccine in healthy adults aged 18\u201359 years: An interim analysis in Indonesia","volume":"39","author":"Fadlyana","year":"2021","journal-title":"Vaccine"},{"issue":"10296","key":"10.1016\/j.vaccine.2022.04.043_b0035","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S0140-6736(21)01429-X","article-title":"Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey","volume":"398","author":"Tanriover","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.043_b0040","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2029111","article-title":"Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study","volume":"18","author":"Wanlapakorn","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"10277","key":"10.1016\/j.vaccine.2022.04.043_b0045","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2022.04.043_b0050","unstructured":"Tanakasempipat P, Thepgumpanat P. Thailand sticks with Sinovac vaccine after cases of \"stroke-like\" side effects. Reuters; 2021 [accessed 06\/23\/2021]. Available from: https:\/\/www.reuters.com\/world\/asia-pacific\/thailand-sticks-with-sinovac-vaccine-after-cases-stroke-like-side-effects-2021-04-21\/."},{"key":"10.1016\/j.vaccine.2022.04.043_b0055","unstructured":"World Health Organization. Recommendation for an emergency use listing of COVID-19 vaccine (Vero cell), inactivated submitted by Sinovac. Geneva: World Health Organization; 2021 [accessed 2021 Jul 18]. Available from: https:\/\/extranet.who.int\/pqweb\/sites\/default\/files\/documents\/SINOVAC_TAG_PEG_REPORT_EUL-Final28june2021.pdf."},{"key":"10.1016\/j.vaccine.2022.04.043_b0060","unstructured":"European Medicines Agency. COVID-19 vaccine AstraZeneca. Amsterdam: European Medicine Agency; 2021 [accessed 2021 Jul 16]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/covid-19-vaccine-astrazeneca-product-information-approved-chmp-29-january-2021- pending-endorsement_en.pdf."},{"issue":"11","key":"10.1016\/j.vaccine.2022.04.043_b0065","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"issue":"12","key":"10.1016\/j.vaccine.2022.04.043_b0070","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41591-021-01548-7","article-title":"Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK","volume":"27","author":"Pouwels","year":"2021","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.043_b0075","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-24285-4","article-title":"COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants","volume":"12","author":"Jalkanen","year":"2021","journal-title":"Nat Commun"},{"issue":"20","key":"10.1016\/j.vaccine.2022.04.043_b0080","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1056\/NEJMoa2102214","article-title":"Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant","volume":"384","author":"Madhi","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.04.043_b0085","doi-asserted-by":"crossref","unstructured":"Li J, Hou L, Guo X, Jin P, Wu S, Zhu J, et al. Heterologous prime-boost immunization with CoronaVac and Convidecia. MedRxiV [Preprint] 2021; September 06, 2021. doi: 10.1101\/2021.09.03.21263062.","DOI":"10.1101\/2021.09.03.21263062"},{"issue":"23","key":"10.1016\/j.vaccine.2022.04.043_b0090","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa0908492","article-title":"Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand","volume":"361","author":"Rerks-Ngarm","year":"2009","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2022.04.043_b0095","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nm881","article-title":"Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans","volume":"9","author":"McConkey","year":"2003","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.vaccine.2022.04.043_b0100","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","article-title":"Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial","volume":"21","author":"Pollard","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"10267","key":"10.1016\/j.vaccine.2022.04.043_b0105","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","article-title":"Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial","volume":"396","author":"Ramasamy","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.vaccine.2022.04.043_b0110","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01930-y","article-title":"Correlates of neutralizing\/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals","volume":"11","author":"Maeda","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.04.043_b0115","doi-asserted-by":"crossref","unstructured":"Crooke SN, Ovsyannikova IG, Poland GA, Kennedy RB. Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25. doi: 10.1186\/s12979-019-0164-9.","DOI":"10.1186\/s12979-019-0164-9"},{"issue":"9","key":"10.1016\/j.vaccine.2022.04.043_b0120","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","article-title":"A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction","volume":"38","author":"Tan","year":"2020","journal-title":"Nat Biotechnol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22004716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:14:19Z","timestamp":1759403659000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22004716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":24,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0264410X22004716"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.043","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunogenicity of heterologous inactivated and adenoviral-vectored COVID-19 vaccine: Real-world data","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.04.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}